MAZE Q4 2024 Earnings — Maze Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MAZEMaze Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$30M

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$241M

Total Liabilities

$44M

Stockholders' Equity

$197M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$30M	-$23M	-29.0%
Net Income	-$30M	-$27M	-11.3%